Wavering calcified amorphous tumour of the heart in a haemodialysis patient

Takayuki Kawata, Hakuoh Konishi, Atsushi Amano and Hiroyuki Daida

INTRODUCTION

Calcified amorphous tumour, a non-neoplastic cardiac mass composed of nodules of calcium on a background of amorphous fibrous material, was first described in 1997 [1]. Since then, few cases have been reported in the English literature. Because the size, origination and configuration of this tumour are variable, it is difficult to distinguish between this tumour and vegetation or other cardiac tumours preoperatively. Here, we describe a patient with a unique calcified amorphous tumour that wavered in the heart.

PATIENT

A 59-year old man, who had been on haemodialysis for 3 years because of diabetic nephropathy, was seen in our hospital, because routine echocardiography showed an intracardiac mobile mass. Routine echocardiography at 1 year before did not show any evidence of this mass. He was asymptomatic and his general condition was normal. Transthoracic and transoesophageal echocardiography revealed a high-echoic swinging tumour that originated from the annulus of the anterior commissure of the mitral valve. Surgical resection was performed to prevent embolization, and his clinical course was excellent.

COMMENT

Calcified amorphous tumour is a non-neoplastic cardiac mass that can mimic neoplasms and cause symptoms due to the obstruction or embolization of calcified fragments. The rarity of this lesion is supported by the fact that a 29-year review at the Mayo clinic yielded only 11 such cases in 1997 [1]. From this previous report, this tumour can originate in any of the four cardiac chambers. The distribution of age and underlying disease, the tumour size and configuration are also variable. Although most
of the sites of the tumour were intracavity and motionless [2, 3]. MAC-related mobile calcified amorphous tumours that can mimic vegetation have been reported [4, 5]. Notably, compared with intracavity tumour, patients with MAC-related calcified amorphous tumour suffered from end-stage renal failure and received haemodialysis, including our case. Although MAC was mild in our case, the lesion was considered a MAC-related calcified amorphous tumour. Mitral annulus involvement in end-stage renal disease patients is most commonly manifested as MAC. A MAC-related calcified amorphous tumour may develop from MAC, and it may be a subtype or atypical variant of MAC [4, 5]. Therefore, this tumour located in a mitral annulus may be noted to end-stage renal disease patients. Because abnormalities of calcium-phosphorus metabolism due to renal dysfunction may contribute to rapid growth of this tumour, calcified amorphous tumour should be considered in cases of haemodialysis, particularly in cases with MAC. Moreover, the adequacy of calcium-phosphorus metabolism may be important for the prevention of MAC and MAC-related calcified amorphous tumour in haemodialysis patients.

**FUNDING**

Conflict of interest: none declared.

**REFERENCES**